Evotec partner Haplogen enters into collaboration with Bayer

Evotec AG announced today that Haplogen GmbH (“Haplogen”), a Vienna-based biotechnology company and collaboration partner of Evotec, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic obstructive pulmonary disease (“COPD”). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partner-haplogen-enters-into-collaboration-with-bayer-5711

Weiterlesen

Evotec AG to report first half-year 2018 results on 09 August 2018

Evotec AG will report its financial results for the first half of 2018 on Thursday, 09 August 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.   Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-to-report-first-half-year-2018-results-on-09-august-2018-5707

Weiterlesen

Evotec repays 50% of € 140 m acquisition loan

Evotec AG announced today that it completes the repayment of 50% of the € 140 m debt bridge facility within the first year of being granted in context of the Aptuit acquisition in 2017. Effective August 2017, Evotec acquired Aptuit, a partner research organisation for integrated outsourced drug discovery and development, for € 253.2 m in cash. This acquisition was financed through existing cash reserves and a new € 140 m senior debt bridge facility. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-repays-50-of-eur-140-m-acquisition-loan-5705

Weiterlesen

Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer

Evotec AG announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of € 4 m to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-milestone-payment-for-start-of-phase-ii-trial-in-its-multi-target-alliance-with-bayer-5703

Weiterlesen

Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development

Evotec AG today announced that the strategic transaction signed on 15 June 2018, to integrate Sanofi’s infectious disease unit including licensing-in the majority of Sanofi’s infectious disease research portfolio, has been successfully closed with effect from 01 July 2018.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-confirm-closing-of-transaction-with-sanofi-to-accelerate-infectious-disease–research-and-development-5701

Weiterlesen

Evotec achieves second milestone in diabetes alliance with Sanofi

Evotec AG today announced that its strategic alliance (TargetBCD) with Sanofi in the field of diabetes has reached its second beta cell therapy milestone, resulting in a payment of € 3 million to Evotec. This milestone was triggered after Evotec met pre-agreed critical success criteria for a potential manufacturing process for generation of human induced pluripotent stem cell (iPSC)-derived beta cells, including the demonstration of upscaling potential and suitability of the cell product for encapsulated beta cell function in diabetes models. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-second-milestone-in-diabetes-alliance-with-sanofi-5699

Weiterlesen

Resolutions of the Annual General Meeting 2018 of Evotec AG

Evotec AG today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2018 with the required majorities. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/resolutions-of-the-annual-general-meeting-2018-of-evotec-ag-5697

Weiterlesen

Evotec and Sanofi sign definitive agreement to combat infectious diseases

Evotec AG today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. This successfully seals the exclusive negotiations between the two companies and completion of the required legal social process, initiated on 08 March 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-sign-definitive-agreement-to-combat-infectious-diseases-5695

Weiterlesen

Evotec forms academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research Center

Evotec AG announced today the formation of the LAB591 academic BRIDGE with Arix Bioscience plc (“Arix”, London Stock Exchange: ARIX ) and the Fred Hutchinson Cancer Research Center (“Fred Hutch”). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-forms-academic-bridge-lab591-with-arix-bioscience-and-fred-hutchinson-cancer-research-center-5693

Weiterlesen